Results 101 to 110 of about 27,995 (239)
Summary Introduction The Procedure Specific Postoperative Pain Management (PROSPECT) collaboration develops evidence‐based recommendations integrating analgesic efficacy, safety and functional recovery. Since publication of the 2021 PROSPECT guidelines for total hip arthroplasty, new evidence, particularly on motor‐sparing regional techniques, has ...
Michele Carella +8 more
wiley +1 more source
The Impact of Common Medications on Male Fertility: An Updated Systematic Review
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli +7 more
wiley +1 more source
Novel approaches for drug development against chronic primary pain: A systematic review
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
Pregabalin for the management of partial epilepsy
Philippe Ryvlin1, Emilio Perucca2, Sylvain Rheims11Service de Neurologie et d’Epileptologie, Hôpital Neurologique, Hospices Civils de Lyon, Université Lyon 1, INSERM U821 and CTRSIDÉE, Lyon, France; 2Clinical ...
Emilio Perucca +2 more
core
Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders
Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman +3 more
wiley +1 more source
Improvement in pain severity category in clinical trials of pregabalin
Bruce Parsons,1 Charles E Argoff,2 Andrew Clair,1 Birol Emir1 1Pfizer, New York, NY, USA; 2Albany Medical Center, Albany, NY, USA Background: Pregabalin is approved by the US Food and Drug Administration for the treatment of fibromyalgia (FM ...
Argoff CE, Clair A, Parsons B, Emir B
core
Pregabalin-induced sexual disinhibition
IntroductionSexual side effects have rarely been reported secondary to treatment with Pregabalin, a structural analogue of the inhibitory neurotransmitter gamma amino butyric acid (GABA).MethodWe present the case of AB, a 27-year-old single man with a ...
B. Hallahan, D. McGuinness, R. Murphy
core +1 more source
Cancer pain: current practice and emerging targets
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye +5 more
wiley +1 more source
Abstract Opioids are prescribed widely for chronic pain despite well‐recognised risks and variable long‐term benefit, reflecting the lack of effective alternatives for many patients. Combination therapies offer a promising strategy to enhance efficacy whilst reducing side effects.
André Mouraux +26 more
wiley +1 more source
Summary Management of type 2 diabetes includes medications that can unintentionally increase obesity and insulin resistance. This unblinded, single‐centre, randomised controlled trial focused on rural Australian adults with type 2 diabetes (aged 18–75 and body mass index [BMI] >30 kg/m2), measuring the effectiveness of a tailored interdisciplinary ...
Giuliana O. Murfet +3 more
wiley +1 more source

